The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor responses and early onset cytokine release syndrome in synovial sarcoma patients treated with a novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer.
 
Mikiya Ishihara
Honoraria - Chugai Pharma; Eisai; MSD; Pfizer; Takara Bio
Research Funding - Takara Bio (Inst); United Immunity (Inst)
 
Shigehisa Kitano
Honoraria - AstraZeneca; AYUMI; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Meiji Seika Kaisha; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sumitomo Group; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; MSD; Novartis; Ono Pharmaceutical
Research Funding - Astellas Pharma; Boehringer Ingelheim; Daiichi Sankyo; Eisai; Gilead Sciences; Ono Pharmaceutical; REGENERON; Takara Bio
 
Hiroyoshi Hattori
Employment - GlaxoSmithKline (I)
 
Yoshihiro Miyahara
Research Funding - BrightPath Biotheraputics (Inst); Takara Bio (Inst)
 
Hidefumi Kato
No Relationships to Disclose
 
Hideyuki Mishima
Honoraria - Chugai Pharma; Takeda
Research Funding - Chugai Pharma
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - ASLAN Pharmaceuticals; Boehringer Ingelheim; Eisai; OncoTherapy Science; Otsuka; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQVIA (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Takeru Funakoshi
Honoraria - Bristol-Myers Squibb Japan; Minophagen Pharmaceuticals; MSD; Novartis; Ono Pharmaceutical
Research Funding - MSD; Ono Pharmaceutical; Zenyaku Kogyo
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan
 
Takashi Kojima
Honoraria - Oncolys BioPharma
Research Funding - Astellas Amgen BioPharama (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Tetsuro Sasada
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Nippon Kayaku
Research Funding - BrightPath Biotheraputics (Inst); Taiho Pharmaceutical (Inst)
 
Eiichi Sato
Expert Testimony - Takara Bio
 
Sachiko Okamoto
Employment - Takara Bio
 
Daisuke Tomura
Employment - Takara Bio
 
Hideto Chono
Employment - Takara Bio
 
Ikuei Nukaya
Employment - Takara Bio
 
Junichi Mineno
Employment - Takara Bio
 
Hiroaki Ikeda
Honoraria - Chugai Pharma; Novartis; Ono Pharmaceutical
Research Funding - Takara Bio
Travel, Accommodations, Expenses - Chugai Pharma; Novartis; Takara Bio
 
Takashi Watanabe
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma
Research Funding - Takara Bio (Inst); United Immunity (Inst)
 
Shinichi Kageyama
Honoraria - Kyowa Hakko Kirin; Sumitomo Dainippon; Takara Bio
Consulting or Advisory Role - Takara Bio
Speakers' Bureau - Kyowa Hakko Kirin; Sumitomo Dainippon
Research Funding - Takara Bio (Inst); United Immunity (Inst)
Travel, Accommodations, Expenses - Kyowa Hakko Kirin; Sumitomo Dainippon; Takara Bio
 
Hiroshi Shiku
Research Funding - Takara Bio (Inst)
Patents, Royalties, Other Intellectual Property - Takara Bio